A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma.

Authors

• E Antonio Chiocca
• Katie M Smith
• Byron McKinney
• Cheryl A Palmer
• Steven Rosenfeld
• Kevin Lillehei
• Allan Hamilton
• Betty K DeMasters
• Kevin Judy
• David Kirn

Publication/Presentation Date

3-1-2008

Abstract

Interferon-β (IFN-β) is a pleiotropic cytokine with antitumoral activity. In an effort to improve the therapeutic index of IFN-β by providing local, sustained delivery of IFN-β to gliomas, the safety and biological activity of a human IFN-β (hIFN-β)-expressing adenovirus vector (Ad.hIFN-β) was evaluated in patients with malignant glioma by stereotactic injection, followed 4-8 days later by surgical removal of tumor with additional injections of Ad.hIFN-β into the tumor bed. Eleven patients received Ad.hIFN-β in cohorts of 2 × 10

Volume

16

Issue

3

First Page

618

Last Page

626

ISSN

1525-0024

Published In/Presented At

Chiocca, E. A., Smith, K. M., McKinney, B., Palmer, C. A., Rosenfeld, S., Lillehei, K., Hamilton, A., DeMasters, B. K., Judy, K., & Kirn, D. (2008). A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. Molecular therapy : the journal of the American Society of Gene Therapy, 16(3), 618–626. https://doi.org/10.1038/sj.mt.6300396

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

28178503

Department(s)

Administration and Leadership

Document Type

Article